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ABSTRACT 
 
Activin-βE mRNA expression was investigated in male and female rats using gel-based and quantitative RT-
PCR, in fetal and post-natal liver during development and in a variety of tissues from 200 gm adult animals. 
Activin-βE expression was also assessed in rat liver after partial hepatectomy, and after repeated toxic insult. 
Male  Sprague  Dawley  rats  were  subjected  to  partial  hepatectomy  or  sham  operations.  Samples  were 
collected from the caudate liver lobe during regeneration, from 12 to 240 hr after surgery. Three groups of 5 
male rats were treated with CCl4 for 0 (control), 5 or 10 weeks, to induce liver fibrosis and cirrhosis. Activin-
βE mRNA was predominantly expressed in liver, with much lower amounts of mRNA observed in pituitary, 
adrenal gland and spleen, in both males and females. Low activin-βE expression was observed in liver at 
fetal day 16, with higher levels seen between post-natal days 3 and 35 and a further increase noted by day 47, 
in both males and females. Liver activin-βE mRNA concentrations did not change from control values 12-72 
hr  after  PHx,  but  significantly  increased  over  six  fold,  168  hr  post-hepatectomy,  when  liver  mass  was 
restored. Activin-βE mRNA was up-regulated after 5 weeks of CCl4 treatment, but not after 10 weeks. The 
changes in activin-βE mRNA concentrations after liver insult did not always parallel those reported for the 
activin-βC subunit, suggesting activin-βE may have an independent role in liver under certain conditions. 
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INTRODUCTION 
 
The activins  belong to the transforming  growth factor-β 
(TGF-β)  gene  family.  Members  of  this  family  share 
structural  similarities,  but  are  diverse  in  their biological 
activities  (Kingsley,  1994).  Activins  are  hetero-  or 
homodimers  of  β-subunits  held  together  by  disulphide 
bonds (Ying, 1988). Five activin subunits (βA-βE) have 
been identified to  date (Ying, 1988; Hotten et al, 1995; 
Fang et al, 1996). 
 
Activin-βC  and  activin-βE  mRNAs  appear  to  be 
predominantly expressed in the liver (Hotten et al, 1995; 
Fang et al, 1996; Lau et al, 1996; Schmitt et al, 1996; Fang 
et al, 1997; Lau et al, 2000), but have also been reported in 
a variety of other tissues (Mellor et al, 2000; O'Bryan et al, 
2000; Rosendahl et al, 2001; Ball et al, 2002; Hashimoto 
et al, 2002; Vejda et al, 2002; Mellor et al, 2003; Gold et 
al, 2004). The predicted mature region of the activin-βE 
subunit gene shows > 60% identity with activin-βC (Fang 
et  al,  1996)  and  both  genes  are  on  closely  linked  loci, 
separated by only 5.5 kb, suggesting tandem duplication of 
an ancestral gene (Fang et al, 1997). The expression of the 
activin-βC  subunit  is  increased  in  the  earlier  stages  of 
cirrhosis development in rat liver when many hepatocytes 
are undergoing apoptosis (Gold et al, 2003) and is down 
regulated  in  the  early  stages  of  liver  regeneration  after 
PHx  in  the  rat,  suggesting  that  it  may  be  a  negative  
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regulator of liver cell growth (Esquela et al, 1997; Zhang 
et  al,  1997).  Similarly,  in  vivo  treatment  of  rats  with 
lipopolysaccharide, as a means of activating the immune 
system  and  the  hepatic  acute  phase  response,  results  in 
increased activin-βE mRNA levels (O'Bryan et al, 2000).  
It has, therefore, been proposed that activin-βE has a role 
in  the  hepatic  inflammatory  response.  Rosendahl  and 
colleagues  demonstrated  the  presence  of  activin-βE 
mRNA in mouse lung using RT-PCR: Activin-βE mRNA 
was  up-regulated  five-fold  during  chronic  airways 
inflammation,  suggesting  this  activin  subunit  may  be 
involved in acute allergic inflammation and may thus be 
important in respiratory pathophysiology (Rosendahl et al, 
2001).  Despite  these  observations,  studies  of  transgenic 
mice  deficient  in  activin-βC,  activin-βE  or  both  genes 
showed  no  deficiencies  in  embryonic  development,  or 
adult female liver function or liver regeneration (Lau et al, 
2000).  These observations suggest redundancy of function 
amongst some of the members of the TGFβ gene family, 
but are hard to reconcile with clear changes in expression 
in response to injury or toxic insult. 
 
In  order  to  investigate  this  apparent  discrepancy,  we 
examined activin-βE mRNA expression during post-natal 
development and in a variety of adult tissues in male and 
female rats. In addition, we have investigated activin-βE 
expression in adult male rat liver in two models of liver 
injury, partial hepatectomy and repeated toxic insult. 
 
MATERIALS AND METHODS 
 
Experimental animals 
All experiments were performed in accordance with the 
New  Zealand  Animal  Welfare  Act  1999,  after  approval 
was granted by the University of Otago Medical School 
Animal  Ethics  Committee.  Rats  were  housed  under 
constant room temperature (22
oC ± 1
oC), with free access 
to food and water, 12 hr light and 12 hr dark cycles and 
were fed rat laboratory pellets. 
 
Developmental studies 
Liver  samples  were  obtained  from  11  fetal  rats  of 
undetermined sex on fetal day 16, from new-born pups at 
postnatal  day  (D)3  and  from  growing  animals  at  D25 
(prepubertal), D35 (peripubertal) and D47 (adult) (n=2-3 
males and females at each time point).   
 
Adult tissue distribution 
The heart, spleen, kidney, lung and adrenal glands were 
collected  from  5  male  and  5  female  200  gm  Sprague 
Dawley rats. The ovaries and uterus were taken in females 
and both testes were collected from males.  The top of the 
skull was removed and samples of frontal cortex and the 
whole  pituitary  were  collected.  All  tissues  were 
immediately  snap-frozen  and  stored  at  -80
oC  for 
subsequent RNA extraction. 
 
Partial hepatectomy 
Sprague  Dawley  rats  (220gm,  n  =  35  males)  were 
randomly  allocated  to  PHx  or  control  sham  operations.  
PHx was carried out according to the method of Higgins 
and  Anderson  (Higgins  et  al,  1932).  Control  operations 
consisted  of  opening  the  abdominal  cavity  and  briefly 
handling  the  liver.  Two  control  and  3  PHx  rats  were 
sacrificed at 12 hr, 24 hr, 48 hr, 72 hr, 96 hr, 168 hr (7 
days)  and  240  hr  (10  days)  post  surgery,  in  three 
independent experiments (Gold et al, 2005). 
 
Repeated toxic insult 
Fifteen  150  gm  male  rats  were  included  in  the  study.  
Micronodular hepatic cirrhosis was induced according to 
the protocol of Proctor and Chatamra (1982) as described 
previously  (Gold  et  al,  2003). After  14  days  of sodium 
phenobarbitone treatment (35mg/100ml in drinking water), 
to increase the sensitivity of the liver to CCl4, rats were 
randomly allocated to one of three groups and treated with 
CCl4  for  0  weeks  (controls),  5  weeks  or  10  weeks. 
Changes in liver architecture were studied histologically as 
described (Gold et al, 2003). 
 
Liver  collection  in  PHx  and  CCl4-treated  animals  
Samples were collected at all time points after PHx and in 
sham operated controls, from the caudate liver lobe, which 
is left undisturbed by the surgery, but does contribute to 
the  restoration  of  liver  mass.  Tissue  was  also  collected 
from the site of liver lobe removal, 12 hr and 24 hr after 
PHx, to determine changes in the concentrations of mRNA 
for  activins-βA,  -βC  and  -βE,  activin  receptor  subunits 
ActRIIA  and  ActRIIB  and  follistatin  at  the  wound  site. 
The site of lobe removal had completely regressed by 24 
hr, therefore, no further time points were collected from 
this site. A portion of the left lateral lobe was collected 
from control and CCl4-treated animals. Liver samples were 
removed and immediately stored at -80
oC for subsequent 
RNA extraction. 
 
RNA extraction 
Total RNA was extracted from 30 mg of tissue using the 
RNeasy Mini Kit (Qiagen Pty. Ltd., Victoria, Australia) 
according to manufacturer’s directions. Whole ovary and 
pituitary (anterior and posterior) were extracted for RNA. 
An equal amount of RNA from each tissue was used for 
generation of first strand cDNA. 
 
Reverse transcription 
Total RNA (1 µg) and 25  mM oligo-dT  primer (Roche 
Molecular  Biochemicals,  Auckland,  New  Zealand)  were 
heated a total volume of 14.5 µl to 65°C for 10 min, to 
disrupt possible secondary structures and then snap cooled 
on ice. 12.5 U MMuLV Reverse Transcriptase (ABgene, 
Epsom,  Surrey,  UK),  1x  reverse  transcription  buffer 
(ABgene) and 1 mM of each deoxy-NTP (ABgene), in a 
final volume of 20 µl, was incubated at 37°C for 50 min, 
heated to 95°C for 2 min and then stored at -20°C. The 
cDNA was used as a template for PCR. 
 
Gel-based PCR 
Primers  for  activin-βE  PCR  were  designed  based  on 
published  rat  and  mouse  sequences  (Fang  et  al,  1996; 
O'Bryan  et  al,  2000;  Vejda  et  al,  2002)  and  GenBank 
sequences  (GenBank  Accession  numbers  NM008382, 
NM031815,  AF140032,  AF89825).  The  activin-βE 
primers  (βEF:  5’  CTG  TGA  CAC  TGG  TTT  GCT  3’; 
βER:  5’  CAG  CTC  CTG  GAA  ATC  GAC  AT  3’)  
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corresponded to rat mRNA nucleotides 76-93 and 949-968 
(NM031815) and were designed so that the amplicon was 
derived  from  two  exons.  Preliminary  PCR  assays  were 
optimised for annealing temperature, number of cycles of 
amplification  and  Mg
++  concentration  as  previously 
described  (Gold  et  al,  2003;  Gold  et  al,  2005)  and  the 
major  liver  amplicon  (895  bp)  was  sequenced  in  both 
directions  to  verify  sequence  identity,  as  previously 
described for activin-βC RT-PCR (Gold et al, 2003).  
 
The β-actin PCR reaction was continued for 20 cycles, as 
described previously (Gold et al, 2003; Gold et al, 2005).  
The activin-βE PCR reaction contained 1 µl of cDNA, 20 
pmol  of  each  primer,  2  µl  10x  reaction  buffer  IV 
(ABgene),  2  mM  MgCl2,  200  µM  of  each  deoxy-NTP 
(ABgene),  1 U Red Hot  Taq  polymerase (ABgene) and 
sterile water to 20 µl. PCR reactions were amplified in a 
Corbett  PC-960  air-cooled  thermocycler  (Corbett 
Research,  NSW,  Australia)  for  25  cycles.  An  initial 
denaturation step at 95
oC for 2 min was followed by 25 
cycles of 30 sec at 95
oC, 30 sec of annealing at 58
oC and 
elongation  for  40  sec  at  72
oC.  Controls  containing  no 
template, or with gDNA or RNA rather than cDNA, were 
run alongside all experimental samples.  PCR products (15 
µl)  were  separated  by  agarose  gel  electrophoresis  and 
quantified  by  densitometry.  Sample  densities  were 
normalised with respect to the density of β-actin mRNA as 
previously described (Gold et al, 2003). Comparison of the 
results  obtained  from  gel-based  PCR  with  quantitative 
PCR showed similar amounts of activin-βE mRNA were 
measured  by  the  two  methods  (data  not  shown),  as 
reported for activin-βC mRNA (Gold et al, 2003). 
  
Gel-based  PCR  assays  to  semi-quantify  activin-βA, 
activin-βC, activin receptor type II subunits ActRIIA and 
ActRIIB  and  follistatin  expression  at  the  site  of  lobe 
removal, were performed exactly as described previously 
(Gold et al, 2005). 
 
Real time RT-PCR 
A  liver  cDNA  of  known  concentration  was  used  to 
construct a standard curve and the same standard cDNA 
was  used  as  a  reference  in  all  assays.  To  ensure 
amplification  was  cDNA-specific,  an  initial  experiment 
was  performed  where  genomic  DNA,  RT-negative  and 
RT-positive  samples  were  run  for  each  primer  pair.  No 
product  was  detected  in  the  genomic  DNA  or  the  RT-
negative samples (data not shown).  Experimental samples 
were  assessed  in  triplicate.  Levels  of  cDNA  were 
quantified relative to the standard curve and normalised to 
β-actin expression. 
The  cDNA  template  was  amplified  in  a  total  reaction 
volume of 20 µl, with 300nM target-specific primers and 
200  nM  fluorescent  probe  (Table  1)  using  the  Taqman 
Universal  PCR  mix  and  the  ABI7700  (PE  Applied 
Biosystems,  Perkin  Elmer  Corporation,  CA,  USA) 
sequence  detection  system  according  to  manufacturer’s 
directions.  Data  were  analysed  using  ABI7700  software 
(PE Applied Biosystems, Perkin Elmer Corporation, CA, 
USA). 
 
Analysis and statistics 
Two independent RNA extractions, duplicate cDNA and 
duplicate  gel-based  PCR  reactions  were  performed  on 
liver samples from male and female animals at different 
developmental ages. Results are presented as the mean ± 
range  of  the  band  densities.  Gel-based  PCR  data  from 
developmental  studies  were  not  compared  statistically.  
Tissue distribution results from quantitative RT-PCR are 
presented as mean ± standard error of 3 independent PCR 
reactions  with  different  cDNAs  from  5  male  and  5 
female rats.   
 
PHx  data  were  log  transformed  and  time  differences 
assessed  by  analysis  of  variance  (ANOVA,  SPSS  for 
Windows 6.1).  Normalised densities are expressed as a 
percentage  of  sham  operated  controls.  Data  from  the 
cirrhosis  studies  are  presented  similarly.  The  tissue 
distribution  of  activin-βE  mRNA,  the  data  on  activin 
subunit, activin receptor subunit and follistatin expression 
at the site of lobe removal (n = 3 animals per time point) 
and  cirrhotic  liver  injury  data  were  analysed  by  Mann-
Whitney U Test (SPSS for Windows 6.1). 
 
RESULTS 
 
Developmental expression of activin-β β β βE mRNA 
Figure 1A shows a representative optimised gel-based RT-
PCR assay for activin-βE and β-actin expression through 
post-natal  development.  A  major  amplicon  at 
approximately 895 bp was observed after 20 PCR cycles.  
To  confirm  amplicon  identity,  PCR  products  were 
sequenced  in  both  directions  using  the  direct-cycle 
method,  by  the  University  of  Otago  Centre  for  Gene 
Research  sequencing  facility.  The  895  bp  band  showed 
99% homology with mouse inhibin C on chromosome 7. A 
minor amplicon of 1100 bp was present in some, but not 
all cDNA samples from adult rat liver. This band was not 
included in analysis as sequencing indicated there was a 
small degree of homology with mouse chromosome 3 and 
thus  it  could  be  non-specific  for  activin-βE.  Figure  1B 
shows the levels of activin-βE mRNA relative to β-actin 
 
Table 1. Quantitative RT-PCR probes and primers. All sequences are depicted as 5’ to 3’. F: forward; R: reverse 
 
activin-βE probe  Fam -CAAAACTCCAACTGGAATTCAGACCT-Tamra 
activin-βE primer F  TTCCTAGCTGATTACCAAACCACTT 
activin-βE primer R  CTCCGCAAGCCGCTAGAG 
β-actin probe  Fam-TTTGAGACCTTCAACACCCCAGCCA –Tamra 
β-actin primer F  CGTGAAAAGATGACCCAGATCA 
β-actin primer R  CACAGCCTGGATGGCTACGT  
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mRNA  in  fetal  rat  liver  and  in  post-natal  liver  during 
development.    Low  amounts  of  activin-βE  mRNA  were 
measured in the livers of fetal rats at F16. An approximately 
7-fold increase in band density was seen by post-natal D3 
and densities remained constant between D3 and D35 for 
both males and females.  A further increase in expression 
was observed at D47.  No attempt was made to compare 
activin-βE concentrations statistically in this experiment.  
 
Tissue distribution of activin-β β β βE mRNA 
Activin-βE  mRNA  was  predominantly  expressed  in  rat 
liver (Figure 2).  There were low amounts of mRNA in 
most  other tissues assessed, particularly in the  pituitary, 
adrenal and spleen. There were no significant differences 
in  the  amounts  of liver  and  pituitary  activin-βE  mRNA 
observed in males and females (liver: p = 0.072; pituitary: 
p = 0.084; Mann-Whitney U Test). 
 
Activin-β β β βE expression after PHx 
PHx rats lost 4% of their body weight post-PHx, and were 
back to pre-operation weight after 60 hours. By 168 hours 
post-PHx, rat body weight was steadily increasing (14% 
compared  to  pre-operation  weight).  In  comparison,  the 
sham  operated  controls  did  not  lose  weight  post-sham 
operation and body weight increased throughout the study 
(25%  increase  by  168  hr).  Normal  liver  cellular 
architecture was restored in sections of liver after 168 hr 
(data not shown). 
 
Activin-βE and β-actin concentrations were measured 
by quantitative RT-PCR in tissue extracts from the site 
of liver lobe removal and from the caudate liver lobe. 
A significant fall (p < 0.005) in the amounts of activin-
βE  mRNA,  relative  to  β-actin  mRNA  concentrations, 
was measured at the site of lobe removal 12 hr and 24 
hr  post-PHx  (Figure  3A).  Activin-βA,  activin-βC, 
ActRIIA,  ActRIIB  and  follistatin  mRNA 
concentrations were measured only at the site of lobe 
removal  by  gel-based  RT-PCR.  Changes  in  the 
expression of these mRNAs relative to β-actin levels at 
the  wound  site,  12  hr  and  24  hr  post-PHx,  are  also 
shown in Figure 3A. This site had completely regressed 
by 24 hr; therefore, no further samples were collected 
from  this  site.  Significant  decreases  in  the  relative 
amount  of  mRNA  were  also  observed  for  activin-βC 
(p<0.001), ActRIIA (p<0.05) and ActRIIB (p<0.001) at 
the  wound  site,  whereas  a  significant  increase  in  the 
amount of activin-βA mRNA was observed 12 hr after 
PHx (p<0.03) and in follistatin mRNA 24 hr after PHx 
(p<0.01) at this site.   
 
 
 
 
Figure 1. (A) A representative gel-based RT-PCR for activin-βE and β-actin. A major amplicon at approximately 895 bp was 
observed in adult rat liver extracts, with a minor amplicon at 1100 bp observed in a small proportion of extracts. The 1100 bp 
amplicon was not included in the densitometric analysis. Samples of liver from male (M) and female (F) rats collected on post-natal 
days (D) 9, 25, 35 and 47 are shown on this gel. Ma; size marker DNA  (B) Mean normalised levels of activin-βE mRNA relative to 
β-actin mRNA in fetal (n = 11, sex not determined) and post-natal male (black bars) and female (grey bars) rat liver during 
development, assessed by gel-based RT-PCR. Results are mean ± SD of 3 independent PCR reactions with cDNAs from 2-3 animals 
per time point.  
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Figure 2.  Distribution of activin-βE mRNA relative to β-actin 
mRNA concentrations in a range of male (n = 5) and female (n = 
5) rat tissues, assessed by quantitative RT-PCR (Taqman). 
Results are mean ± standard error of 3 independent PCR 
reactions with different cDNAs. 
 
 
 
 
 
 
Figure 3. (A) Relative amounts of activin-βA, -βC and βE, 
activin receptor subunits ActRIIA and ActRIIB and follistatin 
(FOLL) mRNAs expressed at the site of lobe removal, around 
the suture, at 12 hr (white bars) and 24 hr post-PHx, measured 
using gel-based RT-PCR.  Significant increases in activin-βA 
mRNA were seen at 12 hr (p<0.03) and in follistatin mRNA at 
24 hr after PHx (p<0.01).  The amounts of all other mRNAs 
were significantly less than those in control liver at both 12 and 
24 hr post-PHx. (B) Activin-βE mRNA, assessed by 
quantitative RT-PCR, in regenerating caudate lobe of the liver, 
after PHx in male Sprague Dawley rats (n = 3 PHx at each time 
point). Data were normalised to β-actin expression and are 
presented relative to mean values in sham-operated control rat 
livers (n = 2 at each time point).  A significant (p = 0.04), six 
fold increase in relative activin-βE concentrations was 
observed 168 hr after PHx, with concentrations returning to 
control values 240 hr post-PHx. 
 
 
 
No significant changes in β-actin mRNA expression over 
time were measured in the caudate lobe  of regenerating 
male rat liver (ANOVA; F = 0.68; p = 0.543). Changes in 
activin-βE expression after PHx, expressed, therefore, as 
amount of mRNA relative to expression in sham control 
livers, are presented in Figure 3B. The mean concentration 
of activin-βE measured in sham-operated control caudate 
liver lobe was 11.3±2.3 µg cDNA/ml extract or 0.56±0.12 
ng cDNA/µg RNA (n = 14 rats). Activin-βE expression in 
the  regenerating  caudate  lobe  was  not  significantly 
changed from sham-operated control values 12-48 hr after 
PHx, but increased 6 fold at 168 hr  (p = 0.040), and fell 
back to control values at 240 hr (p = 0.015) (Figure 3B).  
In a previous study we found lower amounts of βA-activin 
mRNA in the caudate lobe of regenerating liver at 12 and 
24  hr,  and  observed  a  marked  increase  in  βA-activin 
mRNA at 168 hr when liver mass appeared fully restored 
(Gold et al, 2005). 
 
Activin-β β β βE  expression  in  the  development  of  liver 
cirrhosis 
Activin-βE mRNA expression in controls and during the 
development  of  CCl4–induced  cirrhosis  is  shown  in 
Figure 4. Activin-βE mRNA increased significantly after 
5 weeks of CCl4 treatment (p < 0.02, by Mann-Whitney 
U Test), returning to control levels after 10 weeks.   
 
 
 
 
 
 
Figure 4.  Amounts of activin-βE mRNA, relative to β-actin 
mRNA, during the development of CCl4-induced liver cirrhosis. 
Results are mean ± SEM, of n = 5 animals for each experimental 
group. Activin-βE mRNA levels were significantly higher at 5 
weeks than in control livers or after 10 weeks of CCl4 treatment 
(p<0.02).  
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DISCUSSION 
 
Low concentrations of activin-βE were observed by gel-
based  RT-PCR  in  fetal  liver.  In  contrast  to  postnatal 
tissues, the rat fetal liver goes through dynamic changes 
during  its  21-day  gestation  period.  Vassy  et  al  (1988) 
found that at day 12 of gestation, the hepatocytes, which 
are the cellular source of activin-βE secretion (O'Bryan 
et al, 2000) comprised only 35% of the liver volume, and 
between  days  18  and  20,  this  volumetric  fraction 
increased significantly to approximately 70% (Vassy et 
al, 1988). Since the fetal rats used in the present study 
were obtained on day 16 of gestation, a portion of the 
increase  in  activin-βE  expression  between  fetal  and 
postnatal tissues could be accounted for by the fact that 
there were fewer hepatocytes in the fetal tissue samples 
compared with the postnatal samples.  
 
βC-activin  has  been  shown  to  be  growth  inhibitory  in 
liver (Esquela et al, 1997; Zhang et al, 1997; Chabicovsky 
et al, 2003) or growth promoting (Kobayashi et al, 2002; 
Wada  et  al,  2004).  Mellor  et  al  has  shown  βC-activin 
subunit over-expression antagonises activin A by forming 
intracellular heterodimers (Mellor et al, 2000, Mellor et 
al,  2003).  Activin-βE,  like  activin-βC,  may  in  some 
instances  be  a  potent  inhibitor  of  DNA  synthesis 
(Chabicovsky et al, 2003), meaning low levels of activin-
βE expression in fetal tissues would allow liver growth to 
proceed at a rapid rate and up-regulation at the end stages 
of restoration of liver mass (168 hr) may terminate liver 
regeneration.  Wada  et  al  (2004)  propose  that  activin  C 
homodimer,  rather  than  activin  A,  is  formed  in  normal 
liver  and  partial  hepatectomy  may  lead  to  increased 
activin  A,  terminating  liver  regeneration  (Wada  et  al, 
2004). In an earlier study we showed activin homodimers 
(βAβA, βCβC) are present at low to moderate levels in 
control  liver  while  increased  activin  AC  was  evident 
during liver regeneration. Therefore the formation of the 
activin  heterodimer  AE  may  also  antagonise  the 
formation  of  the  activin  A  homodimer  and  allow 
restoration of liver mass. 
 
Despite reports of liver-specific localisation of activin-βE 
mRNA  (Fang  et  al,  1996;  Lau  et  al,  1996;  Fang  et  al, 
1997; Lau et al, 2000), some groups have demonstrated a 
wider tissue distribution (O'Bryan et al, 2000; Rosendahl 
et al, 2001; Hashimoto et al, 2002; Vejda et al, 2002). The 
current study found activin-βE mRNA was predominantly 
expressed  in  the  liver,  but  low  amounts  of  activin-βE 
mRNA were evident in other tissues, notably the pituitary, 
spleen  and  adrenal  gland.  Vejda et al  reported  different 
tissue expression patterns in male and female rats, with 
male skeletal muscle and heart and female kidney showing 
higher amounts of activin-βE mRNA (Vejda et al, 2002). 
In  agreement  with  the  data  presented  by  Vejda  et  al 
(2002), male rat liver expressed slightly higher amounts of 
activin-βE mRNA compared with liver from females, but 
the  differences  were  not  statistically  significant.  The 
differences in  tissue  distribution  between  this  study  and 
those previously reported may be attributable to the age or 
strain of the rats used in the different investigations or may 
reflect differences in the primer sets used.  
Activin-βE  expression  remained  relatively  constant  from 
post-natal  day  3  until  day  35  and  increased  at  day  47, 
around the time of initiation of steroidogenesis in both male 
and female rats (Okatani et al, 1997; Gomez et al, 2002). 
This  peri-pubertal  increase  suggests  hepatic  activin-βE 
expression  may  be  regulated  by  gonadal  steroids.  This 
hypothesis  should  be  investigated  further  using  isolated 
liver cells in primary culture, to identify the cell type that is 
responsive to male and female gonadal steroids.  Lau et al 
(2000) showed that the livers of mice deficient in activin-
βC,  activin-βE,  or  both,  developed  normally  (Lau  et  al, 
2000),  highlighting  the  possibility  of  either  functional 
substitution by other members of the TGFβ family, or lack 
of a regulatory role during normal growth for these activin 
subunits. The post-natal increase in activin-βE expression 
in rat liver observed in the current investigation  may be 
merely the result of an increase in the volumetric fraction 
of hepatocytes in growing liver, rather than suggestive of a 
regulatory role for this peptide in liver growth.   
 
In  contrast,  mRNA  amounts  in  the  sham-operated  adult 
controls were high compared with fetal or immature values 
and  did  not  change  significantly  in  the  caudate  lobe  in 
response  to  PHx,  until  liver  mass  was  restored,  when 
mRNA concentrations increased over six fold (Figure 3B).  
This  suggests  a  “chalone”-like  response,  to  inhibit  cell 
division  or  induce  apoptosis,  as  liver  mass  reaches  an 
optimal size, as has been previously reported (Esquela et al, 
1997; Zhang et al, 1997).  We have previously reported a 
peak of cell division 48-72 hr and an increase in apoptosis 
96-240  hr  post-PHx  in  this  model  (Gold  et  al,  2005). 
However  the  response  of  activin-βE  to  PHx  was  subtly 
different  from  those  of  activin-βC  and  -βA,  which  both 
decreased significantly in the caudate lobe, 12-96 hr after 
PHx (Gold et al, 2005). Takamura et al (2005) studied the 
expression of activin βA, βC and βE mRNA from 0-120 hr 
in response to portal vein ligation (PBL) or PHx (Takamura 
et  al,  2005).  Expression  of  activin  subunit  mRNA  was 
stronger in response to PBL compared to PHx at the early 
time  points  (0-6  hr).  Interestingly  fold  increase  of  all 
activin subunits in both experimental models was less when 
there was increased evidence of proliferating cells (24-72 
hr) perhaps indicating reduced activin subunit expression 
was associated with liver re-growth after injury (Takamura 
et al, 2005). Our study confirms supports and extends this 
work as we assessed mRNA expression post hepatectomy 
until liver mass was completely restored (240 hr). 
 
If  the  relative  abundance  of  mRNA  determines  which 
activin dimers form in vivo, (Mason et al, 1996; Mellor et 
al, 2003) the large peak of activin-βE mRNA at 168 hr 
post-PHx may indicate a change in the relative proportion 
of activins E, AE or CE since both βA and βC mRNA has 
also been shown to be significantly increased at this time 
point  (Gold  et  al,  2005).  While  it  was  not  possible  to 
determine which proteins were present in the tissue in this 
study,  the  possibility  of  an  activin  CE  dimer  has  been 
reported (Vejda et al, 2002). 
 
The PHx study examined activin-βE gene expression in the 
wound  site  and  the  caudal  lobe  of  rat  liver  after  PHx. 
Activin-βE expression decreased significantly at the site of  
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liver lobe removal, suggesting this activin subunit is down-
regulated  in  the  inflammatory  response  at  this  site.  This 
implies that  activin-βE  has a  different  role to activin-βA, 
expression  of  which  is  up-regulated  in  inflammation  and 
wound healing (Yu et al, 1997; de Kretser et al, 1999; Munz 
et al, 1999; Gribi et al, 2001; Munz et al, 2001; Phillips et al, 
2001). We also observed increased activin-βA mRNA at the 
site of lobe removal 12 hr after PHx. Reaction at the site of 
lobe removal was local and separate from that occurring in 
the regenerating caudate liver lobe, implying that activin-βE 
may be differentially regulated or have a different function in 
the two sites, depending on the local cytokine environment.  
 
Activin-βE  mRNA  was  significantly  increased  after  five 
weeks  of  CCl4  treatment,  at  a  time  when  hepatocyte 
apoptosis is significantly increased and proliferation minimal 
(Gold et al, 2003). It has been proposed that activin-βE has a 
role in liver response to inflammation (O'Bryan et al, 2000), 
as  well  as  allergic-airway  inflammation  (Rosendahl  et  al, 
2001).  However  activin-βA  and  activin-βC  mRNA 
concentrations  are  also  raised  after  5  weeks  of  CCl4 
treatment (Gold et al, 2003), so in the liver this response 
appears not to be subunit specific.  Furthermore, activin-βE 
mRNA concentration decreased at the site of lobe removal at 
PHx,  suggesting  expression  is  not  related  to  increased 
inflammatory response. If we consider relative abundance of 
mRNA as an indicator of which dimers may form; βA was 
up-regulated 3 fold, βC 1.8 fold (Gold et al, 2003) and βE 3 
fold, after 5 weeks of CCl4 treatment perhaps indicating an 
activin  AE  dimer  is  more  likely  to  form  leading  to 
hepatocyte  apoptosis  and  early  stage  liver  disease,  rather 
than the end stage cirrhosis observed at 10 weeks. 
 
CONCLUSIONS 
 
In  summary  our  study  demonstrates  activin-βE  mRNA  is 
predominantly expressed in rat liver, with small amounts of 
mRNA being observed in the pituitary, spleen and adrenal 
glands. Increasing amounts of activin-βE mRNA can be seen 
through post-natal development, in parallel with an increase 
in hepatocyte numbers. Activin-βE expression appears to be 
up-regulated  in  the  early  stages  of  chronic  liver  disease, 
rather  than  in  end  stage  cirrhosis,  but  expression  in  the 
caudate lobe is unchanged in the early response to PHx and 
increases markedly just as liver mass is restored. These data 
suggest  activin-βE  may  form  different  dimeric  activin 
species with specific roles in response to acute and chronic 
liver  insult.  While  the  response  of  the  activin-βE  gene 
parallels that of activin-βC in some circumstances, in other 
situations the response is different. Comparison of the results 
from  the  two  liver  insult  models  suggests  the  relative 
abundance  of  activin  subunit  mRNA  may  dictate  which 
activin dimer species are able to form, which in turn may 
determine cellular fate, but final conclusions on the functions 
of the two liver-specific activin subunits will have to await 
further functional biology experiments.  
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